June 15, 2020
The global market for induced pluripotent stem cells (iPSCs), should reach $3.8 billion, growing 9.2% annually, according to the latest report by BCC Research, Induced Pluripotent Stem Cells: Global Markets.
iPSCs are reprogrammed cells from a patient’s body, and are not harvested from embryos, thus avoiding the ethical debates associated with embryonic stem cells. Like other stem cells, they hold the immense promise of transforming into various types of human tissue cells, and potentially representing highly effective treatments for serious illnesses.
Read the full report here: https://www.bccresearch.com/market-research/biotechnology/induced-pluripotent-stem-cells-report.html
“As a breakthrough technology recognized by the Nobel Prize in Physiology or Medicine 2012, iPSCs technology has brought a revolutionary change to modern medicine,” write BCC Research analysts. “iPSC-related products are forming an emerging market despite the fact that clinical applications are still at their early stage. The potential scope of the iPSC market is becoming clear.”
About BCC Research
BCC Research publishes market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering current and emerging industrial and technology sectors. For more information about BCC Research, visit bccresearch.com.
Induced Pluripotent Stem Cells: Global Markets( BIO135C )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.